Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Ophthalmic Drugs Devices Market

ID: MRFR/Pharma/51801-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026

US Ophthalmic Drugs and Devices Market Research Report: Size, Share, Trend Analysis By Product (Drugs, Devices) and By Treatment (Eye Infections, Allergic Conjunctivitis, Dry Eyes Syndrome, Red Eyes, Inflammation, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Ophthalmic Drugs Devices Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Glaucoma
  50.     4.1.2 Cataract
  51.     4.1.3 Retinal Disorders
  52.     4.1.4 Infection
  53.     4.1.5 Dry Eye
  54.   4.2 Healthcare, BY Device Type (USD Billion)
  55.     4.2.1 Surgical Instruments
  56.     4.2.2 Diagnostic Equipment
  57.     4.2.3 Therapeutic Devices
  58.     4.2.4 Contact Lenses
  59.     4.2.5 Intraocular Lenses
  60.   4.3 Healthcare, BY Formulation Type (USD Billion)
  61.     4.3.1 Ophthalmic Solutions
  62.     4.3.2 Ophthalmic Suspensions
  63.     4.3.3 Ophthalmic Ointments
  64.     4.3.4 Ophthalmic Gels
  65.     4.3.5 Ophthalmic Inserts
  66.   4.4 Healthcare, BY Distribution Channel (USD Billion)
  67.     4.4.1 Hospital Pharmacies
  68.     4.4.2 Retail Pharmacies
  69.     4.4.3 Online Pharmacies
  70.     4.4.4 Specialty Pharmacies
  71.   4.5 Healthcare, BY End User (USD Billion)
  72.     4.5.1 Hospitals
  73.     4.5.2 Ophthalmology Clinics
  74.     4.5.3 Ambulatory Surgical Centers
  75.     4.5.4 Home Care Settings
  76. 5 SECTION V: COMPETITIVE ANALYSIS
  77.   5.1 Competitive Landscape
  78.     5.1.1 Overview
  79.     5.1.2 Competitive Analysis
  80.     5.1.3 Market share Analysis
  81.     5.1.4 Major Growth Strategy in the Healthcare
  82.     5.1.5 Competitive Benchmarking
  83.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  84.     5.1.7 Key developments and growth strategies
  85.       5.1.7.1 New Product Launch/Service Deployment
  86.       5.1.7.2 Merger & Acquisitions
  87.       5.1.7.3 Joint Ventures
  88.     5.1.8 Major Players Financial Matrix
  89.       5.1.8.1 Sales and Operating Income
  90.       5.1.8.2 Major Players R&D Expenditure. 2023
  91.   5.2 Company Profiles
  92.     5.2.1 AbbVie Inc (US)
  93.       5.2.1.1 Financial Overview
  94.       5.2.1.2 Products Offered
  95.       5.2.1.3 Key Developments
  96.       5.2.1.4 SWOT Analysis
  97.       5.2.1.5 Key Strategies
  98.     5.2.2 Bausch Health Companies Inc (US)
  99.       5.2.2.1 Financial Overview
  100.       5.2.2.2 Products Offered
  101.       5.2.2.3 Key Developments
  102.       5.2.2.4 SWOT Analysis
  103.       5.2.2.5 Key Strategies
  104.     5.2.3 Regeneron Pharmaceuticals Inc (US)
  105.       5.2.3.1 Financial Overview
  106.       5.2.3.2 Products Offered
  107.       5.2.3.3 Key Developments
  108.       5.2.3.4 SWOT Analysis
  109.       5.2.3.5 Key Strategies
  110.     5.2.4 Novartis AG (US)
  111.       5.2.4.1 Financial Overview
  112.       5.2.4.2 Products Offered
  113.       5.2.4.3 Key Developments
  114.       5.2.4.4 SWOT Analysis
  115.       5.2.4.5 Key Strategies
  116.     5.2.5 Alcon Inc (US)
  117.       5.2.5.1 Financial Overview
  118.       5.2.5.2 Products Offered
  119.       5.2.5.3 Key Developments
  120.       5.2.5.4 SWOT Analysis
  121.       5.2.5.5 Key Strategies
  122.     5.2.6 Johnson & Johnson (US)
  123.       5.2.6.1 Financial Overview
  124.       5.2.6.2 Products Offered
  125.       5.2.6.3 Key Developments
  126.       5.2.6.4 SWOT Analysis
  127.       5.2.6.5 Key Strategies
  128.     5.2.7 Merck & Co Inc (US)
  129.       5.2.7.1 Financial Overview
  130.       5.2.7.2 Products Offered
  131.       5.2.7.3 Key Developments
  132.       5.2.7.4 SWOT Analysis
  133.       5.2.7.5 Key Strategies
  134.     5.2.8 Santen Pharmaceutical Co Ltd (US)
  135.       5.2.8.1 Financial Overview
  136.       5.2.8.2 Products Offered
  137.       5.2.8.3 Key Developments
  138.       5.2.8.4 SWOT Analysis
  139.       5.2.8.5 Key Strategies
  140.   5.3 Appendix
  141.     5.3.1 References
  142.     5.3.2 Related Reports
  143. 6 LIST OF FIGURES
  144.   6.1 MARKET SYNOPSIS
  145.   6.2 US MARKET ANALYSIS BY APPLICATION
  146.   6.3 US MARKET ANALYSIS BY DEVICE TYPE
  147.   6.4 US MARKET ANALYSIS BY FORMULATION TYPE
  148.   6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  149.   6.6 US MARKET ANALYSIS BY END USER
  150.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  151.   6.8 RESEARCH PROCESS OF MRFR
  152.   6.9 DRO ANALYSIS OF HEALTHCARE
  153.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  154.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  155.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  156.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  157.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  158.   6.15 HEALTHCARE, BY DEVICE TYPE, 2024 (% SHARE)
  159.   6.16 HEALTHCARE, BY DEVICE TYPE, 2024 TO 2035 (USD Billion)
  160.   6.17 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  161.   6.18 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
  162.   6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  163.   6.20 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
  164.   6.21 HEALTHCARE, BY END USER, 2024 (% SHARE)
  165.   6.22 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  166.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  167. 7 LIST OF TABLES
  168.   7.1 LIST OF ASSUMPTIONS
  169.     7.1.1
  170.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  171.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  172.     7.2.2 BY DEVICE TYPE, 2026-2035 (USD Billion)
  173.     7.2.3 BY FORMULATION TYPE, 2026-2035 (USD Billion)
  174.     7.2.4 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
  175.     7.2.5 BY END USER, 2026-2035 (USD Billion)
  176.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  177.     7.3.1
  178.   7.4 ACQUISITION/PARTNERSHIP
  179.     7.4.1

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Glaucoma
  • Cataract
  • Retinal Disorders
  • Infection
  • Dry Eye

Healthcare By Device Type (USD Billion, 2026-2035)

  • Surgical Instruments
  • Diagnostic Equipment
  • Therapeutic Devices
  • Contact Lenses
  • Intraocular Lenses

Healthcare By Formulation Type (USD Billion, 2026-2035)

  • Ophthalmic Solutions
  • Ophthalmic Suspensions
  • Ophthalmic Ointments
  • Ophthalmic Gels
  • Ophthalmic Inserts

Healthcare By Distribution Channel (USD Billion, 2026-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies

Healthcare By End User (USD Billion, 2026-2035)

  • Hospitals
  • Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓